Table 2 Baseline characteristics of the 207 kidney transplants included in the study a
A. Recipients | ||||
Women, n (%) | 83 (40.1) | |||
Age at transplantation (years) | 48.1 ± 13.8 (19.0–77.0) | |||
Last PRA > 20%, n (%) | 19 (8.3) | |||
Retransplants, n (%) | 41 (19.8) | |||
HLA mismatch, n (%) | ||||
0–2 | 65 (31.7) | |||
3–4 | 115 (56.1) | |||
5–6 | 25 (12.2) | |||
Delayed Graft Functionbc (DGF), n (%) | 58 (34.0) | |||
Primary kidney disease, n (%) | ||||
diabetes | 21 (10.1) | |||
ADPKD | 34 (16.4) | |||
GN | 83 (40.1) | |||
hypertensive nephropathy | 12 (5.8) | |||
other or unknown | 57 (27.5) | |||
Dialysis before Tx (years) | 4.6 ± 5.1 (0–31.3) | |||
Preemptive Tx, n (%) | 3 (1.4) | |||
Induction with ATG or aIL2, n (%) | 64 (31.5) | |||
Cyclosporine A, n (%) | 53 (25.6) | |||
Tacrolimus, n (%) | 154 (74.4) | |||
Mycophenolic acid preparation, n (%) | 205 (99.0) | |||
Acute rejection within 1 yr, n (%) | 35 (16.9) | |||
B. Transplanted kidneys | ||||
Donor sex (woman), n (%) | 83 (40.3) | |||
Donor age (years) | 44.3 ± 13.9 (13.0–65.0) | |||
Donor cause of deathc, n (%) | ||||
stroke | 110 (60.8) | |||
trauma | 63 (34.8) | |||
other | 8 (4.4) | |||
Preservation with pulsative perfusion, n(%) | 126 (61.2) | |||
TITd (hours) | 26.8 ± 8.1 (5.8–50.5) | |||
Donor MYH9 SNP | n (%) | n (%) | n (%) | HWE p |
rs11089788 | AA: 55 (26.6%) | AC:105(50.7%) | CC: 47(22.7%) | 0.707 |
rs136211 | AA: 21 (10.1%) | AG: 91 (44%) | GG: 95(45.9%) | 0.908 |
rs2239784 | CC: 187 (90.3%) | CT: 20 (9.7%) | TT: 0 (0%) | 0.442 |
rs3752462 | CC: 112 (54.1%) | CT: 79(38.2%) | TT: 16 (7.7%) | 0.580 |
rs5756168 | CC: 3 (1.4%) | CT: 39(18.8%) | TT: 165(79.7%) | 0.691 |
rs4821480 | GG: 1(< 1%) | GT: 27(13%) | TT: 179(86.5%) | 0.987 |